- Conference Article
- 10.1109/asp-dac66049.2026.11420467
LaPOD: Latency Prediction for Real-Time LiDAR Object Detection
- Jan 19, 2026
- Wenjing Xie + 4 more +4
Publications from 2021 to 2026
Showing 10 of 41 papers
LaPOD: Latency Prediction for Real-Time LiDAR Object Detection
Availability, prices and affordability of self-monitoring blood glucose devices: surveys in six low-income and middle-income countries
IntroductionAccessing glucose meters, test strips, lancets and continuous/flash glucose monitoring devices for self-monitoring blood glucose (SMBG) is crucial for the management of diabetes. Yet little is known about access to SMBG devices in low-income and middle-income countries.MethodsIn 2022/2023, facility-based surveys were undertaken in selected regions and sectors in Fiji, Indonesia, Kyrgyzstan, Mali, Peru and Vietnam. Availability and patient prices were collected in public sector outlets (hospital dispensaries/clinics) and private pharmacies in the community by in-person visits (except in Mali where it was collected by phone). Data were also collected in medical device shops (Vietnam), online marketplaces (Indonesia) and online from device manufacturers.Availability was assessed as the percentage of outlets with the device in stock on the day of data collection. Median prices were calculated and reported in US dollars (US$). Affordability was assessed as the number of days’ wages needed by the lowest-paid unskilled government worker to purchase each device. The affordability of self-monitoring was then compared with that of insulin.ResultsSMBG devices were not generally provided to individuals for self-testing by governments in Fiji, Indonesia, Kyrgyzstan and Peru. Public sector availability ranged from 0% to 57% (meters) and 0% to 53% (strips). In private pharmacies, availability was 31% to 100% (meters) and 39% to 100% (strips). Some large regional variations were seen within countries. Median prices for one meter ranged from US$15.62 to US$35.18. For one strip, median prices ranged from US$0.27 to US$0.56. Continuous/flash glucose monitoring devices were only found online at US$88–US$107 per sensor. Between 1.5 and 10.9 days’ wages were needed to purchase 1 meter, and 1.0–12.8 days’ wages for 50 strips. Online purchases of 1-month supply of continuous/flash device sensors required 15–65 days’ wages. The cost of self-testing exceeded the cost of human insulin vials/syringes. However, analogue prefilled pens/pen needles were often higher priced than the cost of self-testing.ConclusionPoor availability and high prices were found for SMBG devices which can impact diabetes management. Prices of meters, test strips and sensors were unaffordable. Pricing for these essential tools requires further investigation including cost of goods sold; government procurement prices and volumes; and price components in supply chains. Accessing SMBG devices must not be considered in isolation to accessing insulin. Governments need to include SMBG devices in their package of essential diabetes services. They must also support ongoing monitoring to ensure people are accessing SMBG devices.
Read moreBreaking barriers: addressing transphobia and advancing transgender rights in the Asia-Pacific and beyond.
Addressing Global Barriers to Paediatric Cochlear Implantation
Acceptance and willingness to pay for COVID-19 vaccines available in Vietnam: an online study during the fourth epidemic wave
COVID-19 vaccines available in Vietnam have different prices, efficacies, and side effects. We studied acceptance and willingness to pay (WTP) for COVID-19 vaccines in Vietnam, using a self-designed online questionnaire. Respondents were 2093 unvaccinated adults. Multiple regression analyses identified factors associated with vaccine acceptance and WTP. Acceptance of free vaccines was around 90% for the three available in Vietnam (Astra Zeneca, SPUTNIK V, and Pfizer-BioNTech). WTP for the same vaccines was about 70%. Vaccine acceptance was associated with being female and/or chronically ill or undergoing COVID-19-related job changes. WTP was associated variously with family economic status, occupational changes due to COVID-19, chronic disease, and perceived risk of infection. Most respondents were willing to be vaccinated and many were willing to pay for it, depending on personal and family circumstances. Vietnam should budget for free vaccines to support those unable to pay.
Read moreRelationship Between Job Satisfaction and Health of Hygienists in Lithuania
The Burden of Snakebite in Rural Communities in Kenya: A Household Survey.
Annually, about 2.7 million snakebite envenomings occur worldwide, primarily affecting those living in rural regions. Effective treatment exists but is scarce, and traditional treatments are commonly used. To inform context-specific policies in Kenya, this study aimed to determine the health-seeking behavior and the health, social, and economic burden of snakebites in rural communities. Nonprobability sampling was used to survey 382 respondents from four snakebite-endemic counties, from February to August 2020, using a structured questionnaire. Descriptive statistics, Fisher's exact tests, binary logistic regressions, and Mantel-Haenszel tests were used for analysis. Life-time experience with snakebites included 13.1% of respondents who reported being personally bitten and 37.4% who reported knowing of a community member being bitten. Respondents reported death after a snakebite in 9.1% of bitten community members and in 14.6% of bitten family members. Risk of snakebite was not significantly associated with sex, educational level, or occupation. Snakebite victims were most often walking (38%) or farming (24%) when bitten. Of those bitten, 58% went to a health facility, 30% sought traditional treatment, and 12% first went to a traditional healer before visiting a facility. Significant differences existed in perceptions on the financial consequences of snakebites among those who had been personally bitten and those who had observed a snakebite. Most commonly mentioned preventive measures were wearing shoes and carrying a light in the dark. Community engagement, including engagement with traditional healers, is needed to reduce snakebites. This should be done through education and sensitization to improve used preventive measures and effective health-seeking behavior.
Read moreAvailability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.
Annually, about 2.7 million snakebite envenomings occur globally. Alongside antivenom, patients usually require additional care to treat envenoming symptoms and antivenom side effects. Efforts are underway to improve snakebite care, but evidence from the ground to inform this is scarce. This study, therefore, investigated the availability, affordability, and stock-outs of antivenom and commodities for supportive snakebite care in health facilities across Kenya. This study used an adaptation of the standardised World Health Organization (WHO)/Health Action International methodology. Data on commodity availability, prices and stock-outs were collected in July-August 2020 from public (n = 85), private (n = 36), and private not-for-profit (n = 12) facilities in Kenya. Stock-outs were measured retrospectively for a twelve-month period, enabling a comparison of a pre-COVID-19 period to stock-outs during COVID-19. Affordability was calculated using the wage of a lowest-paid government worker (LPGW) and the impoverishment approach. Accessibility was assessed combining the WHO availability target (≥80%) and LPGW affordability (<1 day's wage) measures. Overall availability of snakebite commodities was low (43.0%). Antivenom was available at 44.7% of public- and 19.4% of private facilities. Stock-outs of any snakebite commodity were common in the public- (18.6%) and private (11.7%) sectors, and had worsened during COVID-19 (10.6% versus 17.0% public sector, 8.4% versus 11.7% private sector). Affordability was not an issue in the public sector, while in the private sector the median cost of one vial of antivenom was 14.4 days' wage for an LPGW. Five commodities in the public sector and two in the private sector were deemed accessible. Access to snakebite care is problematic in Kenya and seemed to have worsened during COVID-19. To improve access, efforts should focus on ensuring availability at both lower- and higher-level facilities, and improving the supply chain to reduce stock-outs. Including antivenom into Universal Health Coverage benefits packages would further facilitate accessibility.
Read moreAn exploratory focus group study on experiences with snakebites: health-seeking behaviour and challenges in rural communities of Kenya.
Snakebite envenoming is a long-hidden public health threat in the rural communities of Kenya. This study aimed to shed light on the health-seeking behaviour of people bitten by snakes, views on prevention measures and community needs and the consequences for snakebite patients in these areas. Six focus group interviews were conducted in communities in the Kajiado (n=3) and Kilifi (n=3) counties. Traditional first-aid practices such as the use of a tourniquet and/or cutting the wound, use of a black stone and a variety of other traditional remedies were common. Challenges with transportation to health facilities and inadequately resourced facilities complicated accessing medical care. Community members voiced a need to improve access to trained healthcare workers and snakebite treatments at health facilities. While communities had high trust in evidence-based medical care, traditional treatment was often sought, causing delays in timely medical attention. Traditional practices were often used in the home environment and these were not usually administered by a traditional healer. The findings illustrate the need to combine improving the availability of effective snakebite treatment and healthcare worker training on snakebite with community education to reduce the impact of snakebite.
Read moreFailing to address access to insulin in its centenary year would be a catastrophic moral failure